Seeing the successes of other covalent medicines companies, a group of blue-chip investors is lining up to take the next shot on goal.
RA Capital, typically known for its late-stage and crossover investments, is getting in on the ground floor at Hyku Biosciences, a new biotech that emerged from stealth…
Click here to view original post
